Free Newsletter
Pfizer drug safety website draws praise
Pfizer has unveiled a new drug safety section on its website, and so far, critics are giving it a thumbs up. "They've made a good faith effort," Dr. Steve Nissen (photo), Cleveland Clinic's head of cardiology, told the Associated Press. Dr. Harlan Krumholz, director of Yale's Center for Outcomes Research, said, "The spirit of what they're doing is great." And both of them said they hope other drugmakers follow suit.
The site includes sections for patients and for healthcare providers, both of which highlight the fact that every drug has its risks as well as its benefits. And the site includes a boxed link for reporting drug side effects to the FDA. Considering the fact that drug ads are known for racing through the fine print on side effects, Pfizer's frankness about those risks is an obvious departure. "Too long, the perspective presented to the public has been that drugs are some magic bullet...that there's no downside," Nissen said.
- get Pfizer's release
- read the Chicago Tribune story
- check out the WSJ Health Blog post
- see the Pfizer safety site
Related Articles:
AMA calls for tighter DTC regulation
Will consumers help police DTC ads?
Drug websites that catch docs' eyes
Should FDA's info be in all DTC ads?
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: